Clinical Collaboration Unit Translational Immunology, German Cancer Consortium (DKTK), University Hospital Tübingen, Tübingen, Germany; Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany; Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
Department of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany; Cluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany; German Cancer Consortium (DKTK) and German Cancer Research Center (DKFZ), Partner Site Tübingen, Tübingen, Germany.
Mol Cell Proteomics. 2021;20:100022. doi: 10.1074/mcp.R120.002309. Epub 2021 Feb 8.
The approach of peptide-based anticancer vaccination has proven the ability to induce cancer-specific immune responses in multiple studies for various cancer entities. However, clinical responses remain so far limited to single patients and broad clinical applicability was not achieved. Therefore, further efforts are required to improve peptide vaccination in order to integrate this low-side-effect therapy into the clinical routine of cancer therapy. To design clinically effective peptide vaccines in the future, different issues have to be addressed and optimized comprising antigen target selection as well as choice of optimal adjuvants and vaccination schedules. Furthermore, the combination of peptide-based vaccines with other immuno- and molecular targeted therapies as well as the development of predictive biomarkers could further improve efficacy. In this review, current approaches in the development of peptide-based vaccines and critical implications for optimal vaccine design are discussed.
基于肽的抗癌疫苗接种方法已在多项针对各种癌症实体的研究中证明了诱导癌症特异性免疫应答的能力。然而，到目前为止，临床反应仍然仅限于单个患者，并未广泛应用于临床。因此，需要进一步努力改进肽疫苗接种，以便将这种低副作用的治疗方法纳入癌症治疗的临床常规。为了在未来设计出临床有效的肽疫苗，必须解决并优化不同的问题，包括抗原靶标选择以及最佳佐剂和接种方案的选择。此外，将基于肽的疫苗与其他免疫和分子靶向治疗相结合以及开发预测性生物标志物也可以进一步提高疗效。在这篇综述中，讨论了基于肽的疫苗的开发现状以及对最佳疫苗设计的重要影响。
